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Introduction : The study of genetic factors that modify the
individual response to drugs, referred to as “pharmacogenetics”
is a relatively new field, a discipline at the interface between
genetics and clinical pharmacalogy. In the short period since
Motulsky (1) emphasized the importance of genetics to phar-
cology and Vogel coined the term “pharmacogenetics,” an
impressive number of examples in man has accumulated in
which inherited differences account for strikingly exaggerated
responses to drugs, novel drug effects, or lack of effectiveness
of drugs given in the usual dosage. More recently, we have
come to realize that genetic factors are in large measure
responsible for the individual variability in response to drugs.
conferring on each patient a “pharmacologic individuality.”
The objectives of pharmacogenetice include the identi-
fication of genetically controlled variations in response to
drugs and the study of the molecular basis for these conditions,
their clinical significance, and most important, the development
of simple methods by which susceptible individuals can be
recognized before the drug is administered.
Genetic control of drug action : The basic tenets of
pharmacogenetics are simple. The genetic endowment of the
individual, phenotypically expressed in protein structure, con-
centration, and configuration may alter drug action in multiple
ways.
A drug entering the body comes into contact with numerous
enzymes and other proteins. Nearly all drugs undergo enzym-
atically controlled transformations during their passage thro-
ugh the liver and other organs. Theoretically, genetic mutati-
ons that alter the quality of any of these proteins could lead to
a recognizable disturbance in drug-cell interactions. For
instance, variations in enzyme components of drug metabolism
and conjugation may retard inactivation and consequent excre-
tion of drugs, resulting in toxic concentrations after small
doses. They may modify the site of enzymatic attack on the
drug molecule, producing different metabolites with differing
properties. Alternatively genetic mutations may increase the
activity or inducibility of drug-metabolizing enzymes and
prevent the drug from reaching effective concentrations in
plasma or tissues. Structural differences in serum proteins
could presumably change binding affinities and alter the
ratios of bound to free drug. Similarly, aberrant gene products
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at the site of a drug’s action in organs, tissues, or cells may
confer increased or decreased responsiveness to usual therape-
utic concentrations of a drug,
In some subjects, unusual reactions to drugs may be
inherited without the hereditary defect being directly associated
with the pharmacokinetic behaviour or with the usual response
of organs, tissues, or cells to a particular drug. The prototype
of this phenomenon is represented by the syndrome of drug-
induced hemolytic anemia in subjects genetically deficient in
glucose- 6 -phosphate dehydrogenase (G-6-PD) in their
erythrocytes.
Pharmacogenetic conditions may exist due to the action
of a single mutant gene. This leads to discontinuous variation
in the measure of drug action or-metabolism, and the popula-
tion can be divided into two or more groups (with continuous
variation within each group) suggesting single. gene polymor-
phism. The variations most frequently observed have, how-
ever, a Gaussian distribution resulting from polygenic and/or
environmental factors or influences.
Detection of pharmacogenetic conditions : An unexpe-
cted drug response or unusual metabolism is the starting point
of the study detailed studies of the affected patients and their
close relatives show whether the condition is present in other
family members, permitting recognition of the transmission by
classic mendelian inheritance, i.e., as an autosomal dominant
or recessive, or X-linked trait.
A survey in a sample population can be conducted look-
ing for either a distinct subpopulation or for individuals with.
an unusual response. This method was successfully employed
by evans and co-workers (2) In their classical studies on the
inherited variability in the metabolism or inactivation of isoni-
azid. This method; is not favoured, because of ethical consi-
deration and other difficulties.
Another approach is to conduct studies with a small
series of identical and fraternal twins to determine whether an
observed variation in drug response can be attributed primarily
to genetic or environmental factors This is achieved by the
calculation of the heredity co-efficient (H) from the formula :
Variance within pairs Variance within pairs
of fraternal twins – of identical twins
H=    
Variance within pairs
of fraternal twins
The value of H ranges from 0 to 1, from “negligible
hereditary contribution” to “virtually complete hereditary
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influence” (3). A number of drugs such as isoniazid anti-
pyrine, dicumarol and phenylbutazone (4-6) and nortryptiline
(9) have been investigated using this approach. These studies
however, do not permit a distinction between modes of mende-
lian or polygenic inheritance.
Specific pharmacogenetic disorders
Slow and rapid acetylation of isoniazid : lsoniazid is an
antituberculosis drug and the primary step in its metabolism
is acetylation to acetylisoniazid (Fig.1). The metabolizing
enzyme is a hepatic N-acetyltransferase, which displays genetic
polymorphism. Analysis of the inheritance of the two pheno-
types, slow and rapid acetylators of the drug, indicate that
slow metabolism is due to an autosomal recessive gene, and
that slow acetylators are homozygous for the recessive gene;
rapid acetylators could either be heterozygous or homozygous
for the dominant gene. The difference in the two phenotypes
is due to the difference in the quantity rather than the quality
of the enzyme, the rapid acetylators having nearly 4-5 times
the quantity of the enzyme as the slow inactivators (10-12). The
incidence of slow acetylators in different populations varies
remarkably, ranging from about 5% in Canadian Eskimoes to
about 83% in Egyptians (13). Human N-acetyltransferase
catalyzes the acetylation of a number of other drugs such as
sulphadimidine, hydralazine, dapsone and phenelazine, and the
acetylation of these drugs parallels that of isoniazid.
A number of methods involving determination of concen-
trations of isoniazid in serum (13, 14, 15) or the ratio of acety-
lisoniazid to isoniazid in urine collections (16-18) following
dosage with isoniazid have been developed for classifying
subjects as slow or rapid acetylators. Methods based on the
estimation of free and acetylsulphadimidine in blood and urine
following oral administration of sulphadimidine have also been
employed for this purpose (19-21). A simple qualitative test
based on the excretion of free sulphadimidine in urine has also
been developed at our Centre (22)
A number of controlled clinical trials of the treatment of
pulmonary tuberculosis (23, 27) have shown that the rate of
acetylation of isoniazid is of no prognostic significance when
patients are treated with either daily or twice-weekly regimens
containing this drug; however, with once-weekly regimens of
isoniazid, but without rifampicin (15, 25, 28), the response to
treatment in rapid-acetylators was considerably inferior to that
in slow acetylators (Table 1). Detailed pharmacological inves-
tigations undertaken at our Centre (15, 29, 30) have established
that the failure of once-weekly regimens in rapid acetylators
was predominantly due to inadequate exposure (area under the
time-concentration curve) and coverage (hours for which a bac-
teriostatic concentration of isoniazid 0.2 pg/ml is maintained).
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The main adverse reaction during isoniazid therapy is
peripheral neuropathy (22, 23). In studies undertaken at our
Centre (30), it was established that the incidence of this adverse
reaction was related to the dose of isoniazid, and that it was
substantially higher in slow than in rapid acetylators (Table II)
This adverse reaction is caused by the more rapid elimination of
pyridoxine as a hydrazone of isoniazid, and pyridoxine is an
essential co-enzyme required for the formation of Y-aminobu-
tyric acid from glutamic acid. Deficiency of Y-aminobutyric
acid leads to epileptiform convulsions and peripheral neuro-
pathy. This can be overcame with the administration of
prophylactic doses of pyridoxine.
Another adverse reaction encountered during isoniazid
treatment is hepatitis. Mitchell and co-workers (21) have
suggested that isoniazid may be more hepatotoxic for rapid
than for slow acetylators because rapid acetylators might be
expected to form monoacetylhydrazine more rapidly than do
slow acetylators (Fig. 1), and monoacetylhydrazine can be
converted by p-450-dependent hepatic microsomal enzymes to
a potent acylating agent capable of causing hepatic necrosis.
This hypothesis has been refuted on the ground that rapid
acetylators acetylate monoacetylhydrazine more rapidly than do
slow acetylators to the non-toxic diacetylhydrazine and that
exposure of rapid acetylators to monoacetylhydrazine is, in
consequence, similar to that of slow acetylators (29,36) Indeed,
a retrospective analysis of the incidence of hepatitis among 3000
patients with pulmonary tuberculosis during treatment with a
variety of isoniazid-containing regimens without rifampicin has
shown that the incidence was low (1.3%), and that rapid
acetylators were no more prone to develop isoniazid-induced
hepatitis then were slow acetylators (27). This is a remarkable
example of an interaction between genetic and environmental
factors in the pathogenesis of a drug-induced disease.
Slow metabolism of diphenylhydantoin : Diphenylhyd-
antoin is used in the treatment of epilepsy. Over-dose toxicity
was observed in several family members when the drug was
given in the usual doses. Diphenylhydantoin is metabolized
to a p-hydroxy compound (Fig. 2); it has been shown that the
metabolism of this drug-is genetically controlled and that pati-
ents who developed over-dose toxicity are probably deficient
in this microsomal hydroxylase (28). Kutt and co-workers (24)
noted that some patients given both diphenylhydantoin and
isoniazid in the usual-doses developed signs of diphenylhydan-
toin overdosage, and that patients most likely to show intoler-
ance were slow acetylators of isoniazid. It has been established
that this is due to the inhibition by isoniazid of the microso-
mal hydroxylase responsible for the metabolism of diphenylhy-
dantoin.
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Sensitivity to succinylcholine : Succinylcholine is used as
adjunct to anaesthesia. lt is a muscle relaxant and causes
muscle paralysis for a short duration of time. Soon after its
introduction, it was seen that a small number of patients had
prolonged apnea following a single dose. A familial backgro-
und was soon disclosed (7, 25). Succinylcholine, a dicholine
ester of succinic acid, is hydrolyzed by pseudocholine esterase
in serum. Normally the homozygous carrier genotypes being
referred to as Eu Eu , this enzyme rapidly converts succinylcho-
line to succinylmonocholine, an inactive compound, allowing
very little of the parent compound to reach myoneural receptor
sites. In patients with unexpected sensitivity or resistance to
the drug variant forms of the enzyme with altered qualitative
Or quantitative properties have been detected (Table Ill).
The most common variant, so called “atypical” pseudo-
cholinesterase has a lower affinity for choline-esterase subs-
trates and less susceptible to inhibition by dibucaine. Using
the percentage inhibition by dibucaine of esterase activity in
samples of plasma, homozygote and heterozygote carriers of
the gene defects have been identified (25). Sensitivity to
succinyicholine is inherited as an autosomal recessive trait.
Drug-induced hemolytic anemia : A number of individuals
treated with certain drugs (e.g., primaquine) developed hemo-
lytic anaemia, it was shown that these individuals were defici-
ent in glucose-6-phosphate dehydrogenase (G-6-PD) in their
erythrocytes (26). A number of variants of G-6-PG (at least
80) have been identified; these may have an activity ranging
from 0 - 100% of normal, and there are corresponding variat-
ions in the clinical consequences. Thus, one form which
occurs not uncommonly in black Africans has about 15% of
normal activity. Another variant which is most common in
Mediterranean people has an activity of 0-7% of normal. and
predisposes to favism (consumption of feva beans). Four
other types of the enzyme, with activities ranging from 0-26%
of normal appear to be responsible for hemolytic anaemia (27).
G-6-PD catalyses the formation of NADPH (through the
pentose pathway of glucose metabolism), end NADPH is esse-
ntial for maintaining glutathione in its reduced from (Fig. 3).
Reduced glutathione is essential for the conversion of methem-
oglobin (oxidised form) to hemoglobin (reduced form). Lack
or deficiency of G-6-PD, in the presence of several oxidant
drugs, causes a more rapid conversion of reduced glutathione
to the oxidised form; and results in the accumulation of methe-
moglobin, Heinz body formation, hemolysis and hemolytic
anaemia. A number of drugs (28, 29) such as antimalarial%
antibacterials, analgesics and antipyretics are known to
cause methemeglobinemia and hemolysis (Table IV).
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G-6-PD deficiency is determined by a sex-linked gene
carried on the X-chromosome. The X-chromosomes of males
can be normal or defective and two male genotypes “reactor”
or “normal” are expected; females can be divided into three
groups, “reactor”, “intermediate” or “normal” depending on
the presence of two defective X-chromosomes, one normal and
one defective, and two normal X-chromosomes, respectively.
Acetophenetidin and methemoglobinemia : Acetophene-
tidin (phenacetin) is usually metabolized in the body to N-ace-
tylphenetidin (paracentamol), the active ingredient (Fig. 4)
The O-dealkylation is genetically controlled and in individuals
deficient in this enzyme, acetophenetidin is metabolized thro-
ugh an allernate pathway resulting in the formation 2-hydroxy-
phenetidin. This compound is known to be toxic as it causes
methemoglobinemia and hemolysis in G-6-PD def ic ient
individuals (29).
HGPRT deficiency : Allopurinol is used in the treatment of
gout. This drug inhibits the production of uric acid, by two
different mechanisms; it decreases the conversion of hypoxan-
thine and xanthine to uric acid, and it inhibits the synthesis
of purines (30). This latter effect is absent in children with
Lesch-Nyhan syndrome and in some adult. patients with gout,
in whom there is a deficiency of hypoxanthine-guanine phos-
phoribosyl transferase (HGPRT). This enzyme is required to
allopurinol to its corresponding nucleotide, a prerequisite for
the drug’s effect on purine systhesis. These patients are also
unresponsive to this drugs such as 6-mercaptopurine and
azathioprine that require transformation into ribonucleotides
by HmPRT to be active.
Resistance to coumarin anticoagulants : A very unusual
type of pharmacogenetic condition is the hereditary resistance
to anticoumarin drugs such as warfarin. These patients require
a much higher dose of the drug for adequate therapeutic respo-
nse, monitored by the determination of prothrombin activity
(31, 32 33) There were no unusual differences in the rate of
metabolism, binding to plasma proteins or in the physiological
distribution of warfarin in these patients. The unusual hereditary
resistance is believed to be inherited as an autosomal mende-
lian dominant trait (34). Resistant individuals were also
found to have unusual sensitivity to the antidotal effects of
vitamin K. Thesefindings were interpreted to mean that an
enzyme or a recpector site is involved in the synthesis of the
clotting. factors II, VII, IX and X had been modified by genetic
mutation in some way to alter its affinity for both coumarin
anticoagulants and vitamin k.
Conclusion : The examples cited above have been those
whose effects are striking and grossly unusual. There are
bound to be a number of other drugs, whose response may not
be so striking, but nevertheless important. The medical profe-
ssion should be aware of such differences, and the dose of
drugs adjusted accordingly. It may even be necessary to with-
hold certain drugs fear of serious adverse reactions. Some
drugs are capable of producing chromosomal damage leading
to mutagenesis, teratogenesis or carcinogenesis. Drugs should
therefore, be released only after extensive pharmacological
investigations.
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TABLE I
Acetylator phenotype and response to treatment with regimens containing isoniazid in patients with
pulmonary tuberculosis.
Rhythm of drug -administration
Favourable response at 1 year
Slow acetylators Rapid acetylators
Daily 79-88% 84-85%
Twice-weekly
Once-weekly 82-95% 53-76%
Dosage of INH : Daily : 400 mg ;
Intermittent : 15 mg/kg.
TABLE II
Peripheral neuropathy during daily isoniazid treatment
Daily dose of INH (mg)
Slow acetylators Rapid acetylators
Total patients Palients with P.N.* Total patients Patients with P N.*
No. % No. %
100 x 2
200 x 2
400 x 1
600 x 1
0 0
44 6 14 28 0 0
28
50
32 3
2
6
10
*P.N : Peripheral neuropathy
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TABLE Ill
Heriditary variants of plasma cholinesterase and succinylcholice sensitivity.
Type of enzyme Genotype Prevalence Activity
Homozygotes
Usual
Atypical (dibucaine-resistant)
Fluoride resistant
Silent
Heterozygotes
Usual and atypical
Usual and fluoride-resisiant
Usual and silent
Atypical and fluoride-resistant
Atypical and silent
94%
0.04%
Rare
Rare
4%
Rare
0.5%
Very rare
Rare
100%
50%
55%
0.5%
75%
85%
70%
60%
25%
+
E 10% 130%
2
E Very rare 200-300%
cynthiana
TABLE IV
Some drugs and other agents capable of inducing hemolysis in G-6-PD deficient individuals
Primaquine Nitrofurazone*
Pamaquine
Pentaquine
Quinidine*
Acetylsalicylic acid
Acetanilide
Phenacetin
Antipyrine
Nitrofurantion
Furazolidone
Sulphacetamide
Sulphacetamide
Sulphapyridine
Depsone
Chloramphenicol*
Fava beans*
Bacterial pneumonias
Viral respiratory infections
Vitral hepatitis
Diabetic kectoacidosis
*Hemolysis observed principally in the Caucasians
Uremia
